First FDA/Alzheimer’s Disease Allies Meeting
ACT-AD, together with the Alzheimer’s Association and the Alzheimer’s Study Group, hosted and FDA/Alzheimer’s Disease Allies Meeting to stimulate an open discussion with FDA leadership on the subject of clinical meaningfulness in new AD therapies and help advance the dialogue regarding how best to measure the clinical effectiveness of emerging therapies.
See Press Release
Read Alzheimer Research Forum Article
More Upcoming Events
“If You Build It, Will They Come?” Strategies for Alzheimer’s Disease Clinical Trial Recruitment WebinarThe Accelerate Cure/Treatments for Alzheimer’s Disease (ACT-AD) Coalition for an educational webinar on clinical trial…